Cargando…

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bow, Eric J, Vanness, David J, Slavin, Monica, Cordonnier, Catherine, Cornely, Oliver A, Marks, David I, Pagliuca, Antonio, Solano, Carlos, Cragin, Lael, Shaul, Alissa J, Sorensen, Sonja, Chambers, Richard, Kantecki, Michal, Weinstein, David, Schlamm, Haran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374298/ https://www.ncbi.nlm.nih.gov/pubmed/25887385 http://dx.doi.org/10.1186/s12879-015-0855-6

Ejemplares similares

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
por: Auzinger, Georg, et al.
Publicado: (2015)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
por: Auzinger, G, et al.
Publicado: (2013)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

Adverse Event Burden, Resource Use, and Costs Associated with Immunosuppressant Medications for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review
por: Oglesby, A., et al.
Publicado: (2013)

Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?: Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
por: Stemler, Jannik, et al.
Publicado: (2022)

412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis
por: Heimann, Sebastian M, et al.
Publicado: (2018)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
por: Tsai, Naoky, et al.
Publicado: (2012)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

1734. Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience in Colombia
por: Estacio, Mayra, et al.
Publicado: (2019)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
por: Bulpa, Pierre, et al.
Publicado: (2020)

Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia
por: Mau, Lih-Wen, et al.
Publicado: (2019)

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
por: Döring, Michaela, et al.
Publicado: (2012)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

Mechanisms of Antifungal Properties of Metal Nanoparticles
por: Slavin, Yael N., et al.
Publicado: (2022)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial
por: Pappas, Peter G, et al.
Publicado: (2023)

Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
por: Baddley, John W, et al.
Publicado: (2013)

Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients
por: Ramalingam, S., et al.
Publicado: (2006)

Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
por: Pappas, Peter, et al.
Publicado: (2020)

Antifungal prophylaxis in critically ill patients
por: Silvestri, Luciano, et al.
Publicado: (2008)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia
por: Taynton, Thomas, et al.
Publicado: (2022)

Antifungal Prophylaxis in Immunocompromised Patients
por: Vazquez, Lourdes
Publicado: (2016)

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
por: Kansal, Anuraag R., et al.
Publicado: (2021)

Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing
por: Sim, Starling A., et al.
Publicado: (2018)

224. Epidemiology of Bloodstream infections in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients from 2009 to 2018
por: Classen, Annika, et al.
Publicado: (2019)

A Late Phase of Long-Term Synaptic Depression in Cerebellar Purkinje Cells Requires Activation of MEF2
por: Andzelm, Milena M., et al.
Publicado: (2019)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Deemer on technical analysis
por: Deemer, Walter, et al.
Publicado: (2012)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ho9h63v8qkh87tjfokfebc7fse